Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Completed · Not applicable

Conditions studied: Acute Coronary Syndrome

In brief

To determine the rate of symptomatic and asymptomatic gastrointestinal erosions and ulcerations in patients on dual antiplatelet (aspirin and clopidogrel) therapy after percutaneous coronary intervention (PCI).

Key facts

Study ID

NCT00413309

Run by

Brigham and Women's Hospital

People needed

30

Starts

2006-04-01

Expected to finish

2008-12-01

Last updated by the study team

2009-02-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have undergone PCI within the preceding 72 hrs
• Patients on aspirin and clopidogrel
• Age greater than 18 years and less than 80 years
• Written informed consent

You may not qualify if…

• Active bleeding
• Pregnancy
• Patients already on H2 antagonists
• Patients already on PPI
• Patients with implanted cardiac defibrillator (ICD)
• Patients with GI strictures, swallowing disorders, or bowel obstruction and fistulas.
• Patients with significant gastrointestinal diverticular disease
• Patients likely to require MRI imaging during the time the PillCam is still in the digestive tract (8 to 72 hours after the PillCam procedure)

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.